Psoriasis is a common disorder of the skin, immune system, and joints that is influenced by genetic and environmental factors. It can be aggravated or induced by drugs.
Objectives
To identify the major drugs implicated in inducing or exacerbating psoriasis and to discuss their characteristics.
Methods
We performed a PubMed literature search for reviews and case reports on drugs that exacerbate or induce psoriasis. Articles were screened by title and abstract and then examined for their findings and references.
Results
Drugs most often reported to exacerbate or induce psoriasis were β-blockers, lithium, synthetic antimalarials, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, interferons, tetracyclines, tumor necrosis factor-α inhibitors, and steroid withdrawal.
Conclusions
Characterizing drugs that induce or exacerbate psoriasis by latency and type of psoriatic eruption can help guide clinical reasoning. Although a relatively uncommon occurrence, psoriatic lesions can be caused by drugs, allowing astute physicians to recognize and change their management plans accordingly.
AbelE.A., DiCiccoL.M., OrenbergE.K., FrakiJ.E., FarberE.M.Drugs in exacerbation of psoriasis. J Am Acad Dermatol.1986; 15(5 Pt 1): 1007–22.
2.
BakerH.Psoriasis—clinical features. Br Med J.1971; 3(5768): 231–3.
3.
TsankovN., AngelovaI., KazandjievaJ.Drug-induced psoriasis: recognition and management. Am J Clin Dermatol.2000; 1(3): 159–65.
4.
BasavarajK.H., AshokN.M., RashmiR., PraveenT.K.The role of drugs in the Induction and/or exacerbation of psoriasis. Int J Dermatol.2010; 49(12): 1351–61.
TsankovN., KazandjievaJ., DrenovskaK.Drugs in exacerbation and provocation of psoriasis. Clin Dermatol.1998; 16(3): 333–51.
7.
HengM.C., HengM.K.Beta-adrenoceptor antagonist-induced psoriasiform eruption: clinical and pathogenetic aspects. Int J Dermatol.1988; 27(9): 619–27.
8.
HalevyS., FeuermanE.J.Psoriasiform eruption induced by propranolol. Cutis.1979; 24(1): 95–8.
9.
GoldM.H., HolyA.K., RoenigkHHJr.Beta-blocking drugs and psoriasis. a review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol.1988; 19(5 Pt 1): 837–41.
PuigL., GoniF.J., RoqueA.M., BordasF.D., de MoragasJ.M.Psoriasis induced by ophthalmic timolol preparations. Am J Ophthalmol.1989; 108(4): 455–6.
19.
PatelR.V., LebwohlM.In the clinic: psoriasis. Ann Intern Med.2011; 155(3): ITC2–1-15.
20.
GelfandJ.M., DommaschE.D., ShinD.B.The risk of stroke in patients with psoriasis. J Invest Dermatol.2009; 129(10): 2411–8.
21.
KayeJ.A., LiL., JickS.S.Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol.2008; 159(4): 895–902.
22.
YilmazM.B., TurhanH., AkinY., KisacikH.L., KorkmazS.Beta-blocker-induced psoriasis: a rare side effect—a case report. Angiology.2002; 53(6): 737–9.
23.
YeungC.K., ChanH.H.Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol.2004; 5(1): 3–8.
24.
WhiteS.W.Palmoplantar pustular psoriasis provoked by lithium therapy. J Am Acad Dermatol.1982; 7(5): 660–2.
25.
O'BrienM., KooJ.The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol JDD.2006; 5(5): 426–32.
26.
OckenfelsH.M., WagnerS.N., Keim-MaasC., FunkR., NussbaumG., GoosM.Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Arch Dermatol Res.1996; 288(4): 173–8.
27.
BakkerJ.B., PepplinkhuizenL.More about the relationship of lithium to psoriasis. Psychosomatics.1976; 17(3): 143–6.
28.
SkovenI., ThormannJ.Lithium compound treatment and psoriasis. Arch Dermatol.1979; 115(10): 1185–7.
RudolphR.I.Lithium-induced psoriasis of the fingernails. J Am Acad Dermatol.1992; 26(1): 135–6.
31.
SkerrittP.W.Psoriatic arthritis during lithium therapy. Aust N Z J Psychiatry.1987; 21(4): 601–4.
32.
CarterT.N.The relationship of lithium carbonate to psoriasis. Psychosomatics.1972; 13(5): 325–7.
33.
SasakiT., SaitoS., AiharaM., OhsawaJ., IkezawaZ.Exacerbation of psoriasis during lithium treatment. J Dermatol.1989; 16(1): 59–63.
34.
HanadaK., SawamuraD., SoneK., HashimotoI.Can lithium in spring water provoke psoriasis?Lancet.1997; 350(9090): 1522.
35.
WolfR., Lo SchiavoA.Is transglutaminase the mediator between antimalarial drugs and psoriasis?Int J Dermatol.1997; 36(1): 10–3.
36.
VineJ.E., HymesS.R., WarnerN.B., CohenP.R.Pustular psoriasis induced by hydroxychloroquine: a case report and review of the literature. J Dermatol.1996; 23(5): 357–61.
TrnavskyK., ZbojanovaM., VlcekF.Antimalarials in psoriatic arthritis. J Rheumatol.1983; 10(5): 833–4.
39.
WolfR., SchiavoA.L., LombardiM.L., de AngelisF., RuoccoV.The in vitro effect of hydroxychloroquine on skin morphology in psoriasis. Int J Dermatol.1999; 38(2): 154–7.
40.
KuflikE.G.Effect of antimalarial drugs on psoriasis. Cutis.1980; 26(2): 153–5.
41.
AbelE.A.Diagnosis of Drug-Induced Psoriasis. Semin Dermatol.1992; 11(4): 269–74.
42.
SorbaraS., CozzaniE., ReboraA., ParodiA.Hydroxychloroquine in psoriasis: is it really harmful?Acta Derm Venereol.2006; 86(5): 450–1.
43.
KaliaS., DutzJ.P.New concepts in antimalarial use and mode of action in dermatology. Dermatolog Ther.2007; 20(4): 160–74.
44.
HermanS.M., ShinM.H., HolbrookA., RosenthalD.The role of antimalarials in the exacerbation of psoriasis: a systematic review. Am J Clin Dermatol.2006; 7(4): 249–57.
KatayamaH., KawadaA.Exacerbation of psoriasis induced by indomethacin. J Dermatol.1981; 8(4): 323–7.
47.
PowlesA.V., GriffithsC.E., SeifertM.H., FryL.Exacerbation of psoriasis by indomethacin. Br J Dermatol.1987; 117(6): 799–800.
48.
LassusA.A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease. Curr Med Res Opin.1976; 4(1): 65–9.
49.
GreenC.A., ShusterS.Lack of effect of topical indomethacin on psoriasis. Br J Clin Pharmacol.1987; 24(3): 381–4.
50.
MuiM.M., HsiaS.L., HalprinK.M.Further studies on adenyl cyclase in psoriasis. Br J Dermatol.1975; 92(3): 255–62.
51.
VoorheesJ.J.Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses. Arch Dermatol.1983; 119(7): 541–47.
52.
WongE., CampR.D., GreavesM.W.The responses of normal and psoriatic skin to single and multiple topical applications of leukotriene B4. J Invest Dermatol.1985; 84(5): 421–23.
53.
LammersA.M., van de KerkhofP.C.Response of polymorphonuclear leukocytes to topical leukotriene b4 in healthy and psoriatic skin. Br J Dermatol.1987; 116(4): 521–24.
ReshadH., HargreavesG.K., VickersC.F.Generalized pustular psoriasis precipitated by phenylbutazone and oxyphenbutazone. Br J Dermatol.1983; 109(1): 111–3.
56.
Ben-ChetritE., RubinowA.Exacerbation of psoriasis by ibuprofen. Cutis.1986; 38(1): 45.
57.
MeyerhoffJ.O.Exacerbation of psoriasis with meclofenamate. N Engl J Med.1983; 309(8): 496.
58.
PallerA.S., WishnerA., RoenigkHHJr.Meclofenamate for psoriasis. Arch Dermatol.1984; 120(4): 438.
59.
WolfR., DorfmanB., KrakowskiA.Psoriasiform eruption induced by captopril and chlorthalidone. Cutis.1987; 40(2): 162–4.
60.
WolfR., TamirA., BrennerS.Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica.1990; 181(1): 51–3.
61.
ThakorP., PadmanabhanM., JohnsonA., PararajasingamT., ThakorS., JorgensenW.Ramipril-induced generalized pustular psoriasis: case report and literature review. Am J Therapeutics.2010; 17(1): 92–9.
O'ConnellP.G., GerberL.H., DigiovannaJ.J., PeckG.L.Arthritis in patients with psoriasis treated with gamma-interferon. J Rheumatol.1992; 19(1): 80–2.
68.
GeorgetsonM.J., YarzeJ.C., LalosA.T., WebsterG.F., MartinP.Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol.1993; 88(10): 1756–8.
69.
TaylorC., BurnsD.A., WiselkaM.J.Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J.2000; 76(896): 365–7.
70.
LadoyanniE., NambiR.Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol JDD.2005; 4(2): 221–2.
71.
YurciA., GuvenK., TorunE.Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol.2007; 19(9): 811–5.
72.
MakinoY., TanakaH., NakamuraK., FujitaM., AkiyamaK., MakinoI.Arthritis in a patient with psoriasis after interferon-alpha therapy for chronic hepatitis C. J Rheumatol.1994; 21(9): 1771–2.
73.
LombardiniF., TaglioneE., RienteL., PaseroG.Psoriatic arthritis with spinal involvement in a patient receiving alpha-interferon for chronic hepatitis C. Scand J Rheumatol.1997; 26(1): 58–60.
74.
WolfeJ.T., SinghA., LessinS.R., JaworskyC., RookA.H.De novo development of psoriatic plaques in patients receiving interferon alfa for treatment of erythrodermic cutaneous T-cell lymphoma. J Am Acad Dermatol.1995; 32(5 Pt 2): 887–93.
75.
La MantiaL., CapsoniF.Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci.2010; 31(3): 337–9.
76.
FierlbeckG., RassnerG.Treatment of psoriasis and psoriatic arthritis with interferon gamma. J Investig Dermatol.1990; 95(6 suppl): 138S–41S.
77.
FierlbeckG., RassnerG., MullerC.Psoriasis induced at the injection site of recombinant interferon gamma: results of immunohistologic investigations. Arch Dermatol.1990; 126(3): 351–5.
78.
MorhennV.B., Pregerson-RodanK., MullenR.H.Use of recombinant interferon gamma administered intramuscularly for the treatment of psoriasis. Arch Dermatol.1987; 123(12): 1633–7.
79.
ShioharaT., KobayashiM., AbeK., NagashimaM.Psoriasis occurring predominantly on warts: possible involvement of interferon alfa. Arch Dermatol.1988; 124(12): 1816–21.
80.
Di LerniaV.Treatment of psoriasis in patients with hepatitis C virus infection. Clin Exp Dermatol.2011; 36(4): 417.
81.
BehnamS.E., HindiyehR., FifeD.J., JeffesEWIII, WuJ.J.Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol.2010; 35(4): 397–8.
82.
De SimoneC., ParadisiA., CapizziR., CarboneA., SicilianoM., AmerioP.L.Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol.2006; 54(6): 1102–4.
83.
MaglioccoM.A., GottliebA.B.Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol.2004; 51(4): 580–4.
84.
KetikoglouI., KaratapanisS., ElefsiniotisI., KafiriG., MoulakakisA.Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol.2005; 15(2): 107–9.
85.
KartalE.D., ColakH., OzgunesI., UsluerG.Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy.2005; 51(2-3): 167–9.
86.
HellgrenL.Induction of generalized pustular psoriasis by topical use of betamethasone-dipropionate ointment in psoriasis. Ann Clin Res.1976; 8(5): 317–9.
87.
BakerH., RyanT.J.Generalized pustular psoriasis. a clinical and epidemiological study of 104 cases. Br J Dermatol.1968; 80(12): 771–93.
88.
TsankovN., Botev-ZlatkovN., LazarovaA.Z., KostovaM., PopovaL., TonevS.Psoriasis and drugs: Influence of tetracyclines on the course of psoriasis. J Am Acad Dermatol.1988; 19(4): 629–32.
89.
CounisR., KoumanovK., RaulinJ., InfanteR.[Antilipolytic role of tetracycline: inhibition of adenylate cyclase in vitro]. Eur J Biochem.1973; 37(2): 244–7.
90.
PatelR.N., AtturM.G., DaveM.N.A novel mechanism of action of chemically modified Tetracyclines: Inhibition of COX-2-mediated prostaglandin E2 production. J Immunol.1999; 163(6): 3459–67.
91.
ForsterS., IldertonE., SummerlyR., YardleyH.J.The level of phospholipase a2 activity is raised in the uninvolved epidermis of psoriasis. Br J Dermatol.1983; 108(1): 103–5.
92.
CollamerA.N., BattafaranoD.F.Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum.2010; 40(3): 233–40.
93.
BergnerT., PrzybillaB.Psoriasis and tetracyclines. J Am Acad Dermatol.1990; 23(4 Pt 1): 770–1.
94.
Piquero-CasalsJ., Fonseca de MelloA.P., Dal ColetoC., Fonseca TakahashiM.D., Simonsen NicoM.M.Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of hallopeau. Cutis.2002; 70(2): 106–8.
CohenH.B., BeermanH.The use of systemic tetracycline and ultraviolet in psoriasis: a preliminary report. J Invest Dermatol.1965; 44: 365–6.
97.
MouraoA.F., RustinM., IsenbergD.Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: description of 3 cases and Review of the literature. Clin Exp Rheumatol.2010; 28(3): 408–10.
98.
IborraM., BeltranB., BastidaG., AguasM., NosP.Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J Crohn's Colitis.2011; 5(2): 157–61.
99.
GrinblatB., ScheinbergM.The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum.2008; 37(4): 251–55.
100.
AlabedI.B., QushmaqK.A., KhanM.A.Psoriasis Induced by Infliximab in a Saudi patient with Ankylosing Spondylitis. Saudi Med J.2010; 31(9): 1054–6.
101.
FiorinoG., AllezM., MalesciA., DaneseS.Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther.2009; 29(9): 921–7.
102.
ManniE., BarachiniP.Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Int J Immunopathol Pharmacol.2009; 22(3): 841–4.
103.
CollamerA.N., GuerreroK.T., HenningJ.S., BattafaranoD.F.Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum.2008; 59(7): 996–1001.
104.
VereaM.M., Del PozoJ., Yebra-PimentelM.T., PortaA., FonsecaE.Psoriasiform eruption induced by infliximab. Ann Pharmacother.2004; 38(1): 54–7.
105.
PirardD., ArcoD., DebrouckereV., HeenenM.Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology.2006; 213(3): 182–6.
106.
TakahashiH., HashimotoY., Ishida-YamamotoA., AshidaT., KohgoY., IizukaH.Psoriasiform and pustular eruption induced by infliximab. J Dermatol.2007; 34(7): 468–72.
107.
CohenJ.D., BourneriasI., BuffardV.Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol.2007; 34(2): 380–5.
108.
CuchacovichR., EspinozaC.G., VirkZ., EspinozaL.R.Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between tnf-alpha and IFN-alpha?J Clin Rheumatol.2008; 14(6): 353–6.
109.
SfikakisP.P., IliopoulosA., ElezoglouA., KittasC., StratigosA.Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum.2005; 52(8): 2513–8.
110.
WollinaU., HanselG., KochA., SchonlebeJ., KostlerE., HaroskeG.Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol.2008; 9(1): 1–14.
111.
CarterJ.D., GerardH.C., HudsonA.P.Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis.2008; 67(8): 1181–3.
112.
KaryS., WormM., AudringH.New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis.2006; 65(3): 405–7.
113.
BovenschenH.J., KopE.N., Van De KerkhofP.C., SeygerM.M.Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatol Treat.2006; 17(6): 381–33.
Borras-BlascoJ., Gracia-PerezA., Nunez-CornejoC.Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther.2008; 33(3): 321–5.
116.
MortelM.R., EmerJ.Prospective new biologic therapies for psoriasis and psoriatic arthritis. J Drugs Dermatol JDD.2010; 9(8): 947–58.
117.
GuptaA.K., SibbaldR.G., KnowlesS.R., LyndeC.W., ShearN.H.Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol.1997; 36(5 Pt 2): 858–62.
118.
WachF., StolzW., HeinR., LandthalerM.Severe erythema anulare centrifugum-like psoriatic drug eruption induced by terbinafine. Arch Dermatol.1995; 131(8): 960–1.
119.
SzepietowskiJ.C.Terbinafine exacerbates psoriasis: case report with a literature review. Acta Dermatovenerologica Croatica ADC.2003; 11(1): 17–21.
120.
FisherD.A., EliasP.M., LeBoitP.L.Exacerbation of psoriasis by the hypolipidemic agent, Gemfibrozil. Arch Dermatol.1988; 124(6): 854–5.
121.
ProkschE.[Antilipemic drug-induced skin manifestations]. Der Hautarzt Z Dermatol Venerol Verwandte Gebiete.1995; 46(2): 76–80.
122.
SpencerJ.M., SilversD.N., GrossmanM.E.Pustular eruption after drug exposure: is it pustular psoriasis or a pustular drug eruption?Br J Dermatol.1994; 130(4): 514–9.
123.
IsogaiZ., SunoharaA., TsujiT.Pustular drug eruption due to bacampicilin hydrochloride in a patient with psoriasis. J Dermatol.1998; 25(9): 612–5.
124.
YamamotoM., IkedaM., KodamaH., SanoS.Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol.2008; 35(11): 732–6.
KoJ.M., GottliebA.B., KerbleskiJ.F.Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat.2009; 20(2): 100–8.
